WuXi PharmaTech and Eli Lilly are partnering to develop and commercialize a once-daily oral medication in China to address cardiovascular risk in patients with dyslipidemia.

Discovered by Lilly, the molecule could reduce cardiovascular events in high-risk patients with elevated LDL cholesterol and triglycerides.

Under the agreement, WuXi, China’s largest CRO, will be responsible for regulatory, development and manufacturing activities in that country, while Lilly will oversee commercial activities. Financial terms of the deal were not disclosed.